Oncology

Latest News

In the phase 3 IMforte trial, patients with extensive-stage small cell lung cancer experienced clinically meaningful benefits with maintenance lurbinectedin plus atezolizumab vs atezolizumab. | Image credit: appledesign - stock.adobe.com

Lurbinectedin Plus Atezolizumab Maintenance Shows Improved Survival vs Atezolizumab in SCLC

By Rose McNulty

May 22nd 2025

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

By Laura Joszt, MA
Eileen Peng, PharmD

May 21st 2025

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com

Novel, Noninvasive Skin Cancer Detection Method Shows Promise

By Jared Kaltwasser

May 18th 2025

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Evolution of the ACO Model to Meet the Needs of Oncology Patients and Payers

September 27th 2016

Evolution of the ACO Model to Meet the Needs of Oncology Patients and Payers

Julian Malinak, MPH, finance lead for the pioneer accountable care organization (ACO) and next generation ACO models and technical advisor for financial policy at CMS Innovation Center, explained that CMS, as well as other organizations, are pushing away from the traditional fee-for-service methods by creating delivery models like ACOs and employing various tools and services, such as bundled payments, and are beginning to examine these methods in the oncology setting.

Evaluation of Options and Outcomes in a "Me Too" Market

September 27th 2016

Evaluation of Options and Outcomes in a "Me Too" Market

In the past 5 years, the FDA has approved 52 new agents for oncology use, and 24 of those agents have novel mechanisms, explained Stacey W. McCullough, PharmD, senior vice president of Pharmacy at Tennessee Oncology, PLLC, during her presentation at The American Journal of Managed Care’s 4th Annual Patient-Centered Oncology Care Meeting. With these emerging options in oncology care, there are 3 things to consider when choosing the appropriate option for the patient, she said.

September 26th 2016

A New Biomarker Predicts Response to Pembrolizumab in Advanced Melanoma

Surabhi Dangi-Garimella, PhD

A new study by researchers at the Perelman School of Medicine has identified a predictive biomarker in stage IV patients with melanoma being treated with the pembrolizumab.

September 23rd 2016

UnitedHealth's 2017 Formulary to Support Generic and Biosimilar Drugs

Surabhi Dangi-Garimella, PhD

UnitedHealth has posted a presentation on its website that provides an update to its pharmacy benefits and prescription drug lists for 2017.

September 22nd 2016

Cancer Prevention Possible Through Lifestyle Control, Says JAMA Oncology Study

Surabhi Dangi-Garimella, PhD

Research published in the journal JAMA Oncology argues that major lifestyle changes can significantly delay the onset of cancer.

September 22nd 2016

Carolina Breast Cancer Study Reinforces Relation Between Racial Disparity and QOL

Surabhi Dangi-Garimella, PhD

Research conducted at the University of North Carolina Lineberger Comprehensive Cancer Center has found that white women performed better than black women on physical and functional health-related quality-of-life (HRQOL) scores, but not spiritual HRQOL.

September 20th 2016

Colombia Takes a Stand on Price of Novartis' Leukemia Drug

Surabhi Dangi-Garimella, PhD

Colombia has decided to slash the price of imatinib mesylate (Gleevec), manufactured by Novartis, by nearly half.

September 20th 2016

Improved Design, Access, and Transparency of Trials Essential for Success of Cancer Moonshot

Surabhi Dangi-Garimella, PhD

The National Cancer Institute's Cancer Moonshot initiative received yet another boost following Vice President Joe Biden’s announcement of several activities to accelerate the pace of oncology clinical research.

September 19th 2016

Managing Neutropenia in Patients With Soft Tissue Sarcomas

Using prophylaxis with biosimilar granulocyte colony-stimulating factor can reduce the severity of neutropenia in patients with soft tissue sarcoma.

This Week in Managed Care: September 17, 2016

September 17th 2016

This Week in Managed Care: September 17, 2016

This week, the top managed care stories included news that Risa Lavizzo-Mourey, MD, MBA, will be leaving the Robert Wood Johnson Foundation, a report that obesity rate in the military are also on the rise, and CMS denied Ohio's proposal to charge fees for Medicaid.

September 16th 2016

ASCO President Dr Daniel F. Hayes Applauds Recommendations for Cancer Moonshot

Surabhi Dangi-Garimella, PhD

The American Journal of Managed Care reached out to Daniel F. Hayes, MD, FASCO, 2016-2017 president of the American Society of Clinical Oncology (ASCO), to understand his perception of how the recommendations of the Cancer Moonshot initiative's Blue Ribbon Panel would impact cancer care in the United States.

September 16th 2016

Obesity: A Growing Burden for Cancer Survivors

Patients with a history of cancer were more likely to suffer from obesity than the general population. This incidence was even greater in patients who were survivors of colorectal and breast cancers.

September 16th 2016

NCHS Report: Rising Survivorship in Pediatric Cancers, Brain Cancer Leading Cause of Death

Surabhi Dangi-Garimella, PhD

There has been a steady decline in death rates among children and adolescent patients diagnosed with cancer (ages 1 to 19 years), minus gender or racial disparity, between 1999 and 2014, according to a new report from the National Center for Health Statistics.

September 15th 2016

FDA Advisory Forces Company to Suspend US Sale of Screening Test

Surabhi Dangi-Garimella, PhD

Following an FDA advisory on ovarian cancer screening tests, London-based Abcodia has announced that it will temporarily stop sales of its Risk of Ovarian Cancer Algorithm test in the United States.

September 15th 2016

Oncotype DX May Not Be Economical for Decisions on Adjuvant Radiation

Surabhi Dangi-Garimella, PhD

A cost-effectiveness analysis has found that Oncotype DX may not be economical to make clinical decisions on adjuvant radiation treatment in patients with DCIS.

September 14th 2016

Intervention Improved Oncologist-Patient Communication, Not QOL or Hospice Use

Surabhi Dangi-Garimella, PhD

A study published in JAMA Oncology has found that interventions to improve patient-centered communication was successful in patients with advanced cancer, but it failed to improve quality of life (QOL), patient-physician relation, or healthcare utilization toward the end of life.

September 13th 2016

Daratumumab Lengthens PFS in Multiple Myeloma, but Increases Risk of Neutropenia

Although daratumumab reduced the risk of disease progression and death for patients with multiple myeloma, the drug was associated with a higher rate of neutropenia.

September 13th 2016

Growing Role of Genetic Counselors Could Improve Efficacy of Cancer Diagnosis and Treatment

Surabhi Dangi-Garimella, PhD

Insurance companies are making it mandatory for individuals to speak with qualified genetic counselors prior to testing for some hereditary cancers.

September 12th 2016

Study Finds Majority Users of Oregon's Death With Dignity Act Had Cancer

Surabhi Dangi-Garimella, PhD

A study presented at the 2016 Palliative Care in Oncology Symposium has found that a majority users of the provisions under Oregon's Death With Dignity Act had cancer and most of them chose to die at home.

This Week in Managed Care: September 10, 2016

September 10th 2016

This Week in Managed Care: September 10, 2016

This week, the top stories in managed care were poll results that show Hillary Clinton is more trusted than Donald Trump when it comes to healthcare, multiple studies highlighting remaining disparities in healthcare, and results of a digital diabetes self-management program.

September 9th 2016

Early Results From Juno's CAR-T Cell Therapy Promising in NHL

Surabhi Dangi-Garimella, PhD

An early-phase, dose-finding study using a defined composition of chimeric antigen receptor-T cells, in patients with non-Hodgkin lymphoma, shows promise.

September 9th 2016

5 Recent Developments in Cancer Immunotherapy

Surabhi Dangi-Garimella, PhD

An update on some of the recent developments in the field of immuno-oncology.

September 8th 2016

Family Caregivers of Cancer Patients Vulnerable to Depression, Anxiety

Surabhi Dangi-Garimella, PhD

Nearly 25% to 33% of family caregivers across the United States tend to ignore their own needs, resulting in poorer self-care and symptoms of depression and anxiety, according to a research study to be presented at the 2016 Palliative Care in Oncology Symposium.

September 8th 2016

Most US Adults Favor Prohibiting Tobacco Sales in Retail Pharmacies

More communities across the country have implemented policies prohibiting the sale of tobacco products in retail pharmacy stores in an effort to respond to pharmacists’ concerns about their professional obligation to promote health and wellness among patrons in their stores.

September 7th 2016

Panel Delivers Recommendations for the Cancer Moonshot

Surabhi Dangi-Garimella, PhD

A Blue Ribbon Panel of experts from diverse healthcare fields has provided preliminary recommendations to achieve the objectives of the government's Cancer Moonshot initiative.

September 7th 2016

Pembrolizumab's Breakthrough Toughens the Playing Field in NSCLC

Surabhi Dangi-Garimella, PhD

The FDA has accepted for priority review the supplemental Biologics License Application for Merck's pembrolizumab (Keytruda).

September 6th 2016

Whole-Brain Radiotherapy Unnecessary for Brain Metastases in Patients With NSCLC

Surabhi Dangi-Garimella, PhD

Patients with non-small cell lung cancer whose disease has metastasized to the brain can do without whole-brain radiotherapy, according to a new study published in the journal Lancet.

This Week in Managed Care: September 3, 2016

September 3rd 2016

This Week in Managed Care: September 3, 2016

This week in managed care, the top stories included proposals from CMS to shore up the Affordable Care Act's marketplaces, research that highlighted the link between duration of obesity and cancer risk for women, and the results of an FDA diabetes workshop.

September 2nd 2016

Information Disparity a Major Concern of Breast Cancer Survivors

Surabhi Dangi-Garimella, PhD

Researchers at the Sidney Kimmel Cancer Center collated concerns of African American breast cancer survivors to find that medical mistrust was a commonly raised issue.

September 1st 2016

Study Highlights Inconsistent Cancer Screening Guidelines Among High-Risk Transplant Patients

Surabhi Dangi-Garimella, PhD

Results of a new study published in the American Journal of Transplantation has found that international guidelines lack standardization on screening recommendations for solid organ transplant recipients.

...

91 92 93 94 95 96 97 98 99

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions